Spero Therapeutics

176 articles about Spero Therapeutics

• Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories

  7/5/2021

  Everest Medicines announced that Spero Therapeutics, Inc., a licensing partner of Everest Medicines, entered into a regional licensing agreement with Pfizer Inc. for SPR206, Spero's intravenously -administered next-generation polymyxin product candidate being developed to treat serious multi-drug resistant Gram-negative infections in the hospital setting.

• Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 02, 2021

  7/2/2021

  Spero Therapeutics, Inc. announced that on June 30, 2021, the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 85,650 shares of its common stock to nine new employees under the Spero Therapeutics, Inc.

• Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206

  6/30/2021

  Spero Therapeutics, Inc announced that Pfizer Inc. has made a $40 million equity investment in Spero as part of the Pfizer Breakthrough Growth Initiative, a program focused on funding innovative science to meet patient needs.

• 

  Clinical Catch-Up: June 14-18

  6/21/2021

  It was another busy week of clinical trial announcements. Here’s a look.

• Spero Therapeutics Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of SPR206

  6/15/2021

  Spero Therapeutics, Inc.  today announced the initiation of two Phase 1 trials of SPR206, an intravenously (IV)-administered next-generation polymyxin product candidate.

• Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases to Support the Development of SPR206

  5/17/2021

  The National Institute of Allergy and Infectious Diseases will fund the continued clinical development of product candidate SPR206

• Spero Therapeutics to Participate at the Berenberg Conference USA

  5/13/2021

  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat at the Berenberg Conference USA,

• Spero Therapeutics Announces First Quarter 2021 Operating Results and Provides Business Update

  5/6/2021

  Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, announced financial results for the first quarter ended March 31, 2021 and provided a business update.

• Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 30, 2021

  4/30/2021

  Spero Therapeutics, Inc. announced that on April 30, 2021, the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 28,600 shares of its common stock to three new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan.

• Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021

  4/29/2021

  Spero Therapeutics, Inc. announced that it will host a conference call and live audio webcast on May 6, 2021 at 4:30 p.m. ET to report its first quarter 2021 financial results and provide an update on its business and pipeline.

• Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 31, 2021

  3/31/2021

  Spero Therapeutics, Inc. announced that on March 31, 2021 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 22,050 shares of its common stock to three new employees under the Spero Therapeutics, Inc.

• Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business Update

  3/11/2021

  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced financial results for the fourth quarter and full-year ended December 31, 2020 and provided a business update.

• Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021

  3/3/2021

  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on March 11, 2021

• Spero Therapeutics to Present at Investor Conferences in March

  2/25/2021

  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present at the following investor conferences in March 2021

• 

  Clinical Catch-Up: February 1 – February 5

  2/8/2021

  It was a busy week for clinical trial updates. Here’s a look.

• Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial

  2/5/2021

  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the United States Food and Drug Administration (FDA) informed Spero that a clinical hold has been placed on its Phase 2a clinical trial of SPR720,

• Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 29, 2021

  1/29/2021

  Spero Therapeutics, Inc. announced that on January 29, 2021 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 74,300 shares of its common stock to six new employees under the Spero Therapeutics, Inc.

• Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBr

  1/21/2021

  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,889,587,

• Everest Medicines Announces Amended Agreement with Spero Therapeutics

  1/18/2021

  Spero will assign relevant SPR206 patents to Everest Medicines in Greater China, South Korea and certain Southeast Asian countries

• Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer

  12/17/2020

  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Satyavrat “Sath” Shukla, CFA, as Chief Financial Officer, effective as of January 4, 2021